Search Results

FDA

Occlutech(R) Announces FDA Approval of its Occlutech(R) ASD Occluder and Occlutech(R) Pistol Pusher, a Minimally Invasive Cardiac Device and Delivery System to Treat Atrial Septal Defects

Occlutech Holding AG Occlutech ASD Occluder delivers positive procedural outcomes with strong efficacy and a low rate of complications.

January 8, 2024

·

6 min read

Occlutech Q1 2023 - Growth Momentum with Increased Sales and Marketing Activities

Occlutech Holding AG is a leading specialist provider of minimally invasive structural heart implants.

May 26, 2023

·

5 min read

Business

Occlutech Announces Change to the Executive Management Team

Occlutech Holding AG Occlutech Holding AG, one of the world’s leading providers of minimally invasive structural heart disease devices, appoints Dr. Morwan Choli as the new Vice President of Regulatory Affairs & Quality.

February 1, 2023

·

2 min read

Business

Occlutech Year-end Report 2022 - Significant Uptick in Sales Growth as Transformation Processes are Reaching an End

Occlutech Holding AG is a leading specialist provider of minimally invasive structural heart implants.

May 3, 2023

·

5 min read

Occlutech Announces First Patient Enrollment in Important US Pivotal Study for the Atrial Flow Regulator (FROST-HF)

Occlutech Holding AG, one of the world’s leading providers of minimally invasive structural heart disease devices, continues its progress in the US market.

March 13, 2023

·

6 min read

Policy

Occlutech Continues its Progress in US FDA Study OCCLUFLEX – Enrolls First Patient in Europe

Occlutech Holding AG, one of the world’s leading providers of minimally invasive structural heart disease devices, continues its progress in the US market.

January 31, 2023

·

3 min read

Occlutech Receives Subscription Commitment of Bonds Amounting to EUR 40 million in Nominal Value Under a Total Frame of EUR 75 million to Finance US Expansion and Growth

Occlutech Holding AG, one of the world’s leading providers of minimally invasive structural heart disease devices, receives subscription commitment subject to certain conditions, of bonds to an aggregated amount of EUR 40 million.

April 5, 2023

·

2 min read

Business

Occlutech Announces New Member to the Executive Management Team by Appointing Chief Medical Officer

Occlutech Holding AG, one of the world’s leading providers of minimally invasive structural heart disease devices, has appointed Jozef Bartunek, MD, PhD, as new Chief Medical Officer, thus expanding its Executive Management Team.

November 1, 2022

·

3 min read

Business

Occlutech Q2 2022 - Positive Revenue Growth and Important Milestones Achieved in the Strategic US Market

Occlutech Holding AG is a leading specialist provider of minimally invasive structural heart implants.

August 24, 2022

·

5 min read

Business

Occlutech Announces Changes to the Executive Management Team

Occlutech Holding AG, a leading specialist provider in minimally invasive structural heart implants has changed its Executive Management Team with three new members.

May 31, 2022

·

2 min read